64 related articles for article (PubMed ID: 25130802)
1. [Bioinformatic analysis of chronic myeloid leukemia progression and preliminary experimental verification].
Zhang JF; Liu XL; Lin YD; Pan JW; Xu N
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Aug; 22(4):909-13. PubMed ID: 25130802
[TBL] [Abstract][Full Text] [Related]
2. Chronic myelogenous leukemia molecular signature.
Nowicki MO; Pawlowski P; Fischer T; Hess G; Pawlowski T; Skorski T
Oncogene; 2003 Jun; 22(25):3952-63. PubMed ID: 12813469
[TBL] [Abstract][Full Text] [Related]
3. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
Ferri C; Bianchini M; Bengió R; Larripa I
Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
[TBL] [Abstract][Full Text] [Related]
4. [Identification of differentially expressed genes related to blastic crisis in chronic myeloid leukemia].
Luo X; Zhang J; Liu X; Du Q; Xu N; Xu L; Huang B; Xiao X
Nan Fang Yi Ke Da Xue Xue Bao; 2012 Jun; 32(6):840-2. PubMed ID: 22699066
[TBL] [Abstract][Full Text] [Related]
5. [Differential expression genes in various phases of chronic myeloid leukemia by cDNA microarray].
Gao SJ; Zhu X; Yao C; Li W; Wang GJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Jun; 18(3):575-8. PubMed ID: 20561404
[TBL] [Abstract][Full Text] [Related]
6. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
[TBL] [Abstract][Full Text] [Related]
7. BAX/BCL-XL gene expression ratio inversely correlates with disease progression in chronic myeloid leukemia.
Gonzalez MS; De Brasi CD; Bianchini M; Gargallo P; Moiraghi B; Bengió R; Larripa IB
Blood Cells Mol Dis; 2010 Oct; 45(3):192-6. PubMed ID: 20728382
[TBL] [Abstract][Full Text] [Related]
8. Molecular signature of CD34(+) hematopoietic stem and progenitor cells of patients with CML in chronic phase.
Diaz-Blanco E; Bruns I; Neumann F; Fischer JC; Graef T; Rosskopf M; Brors B; Pechtel S; Bork S; Koch A; Baer A; Rohr UP; Kobbe G; von Haeseler A; Gattermann N; Haas R; Kronenwett R
Leukemia; 2007 Mar; 21(3):494-504. PubMed ID: 17252012
[TBL] [Abstract][Full Text] [Related]
9. Characteristics of the TCR Vβ repertoire in imatinib-resistant chronic myeloid leukemia patients with ABL mutations.
Xu L; Lu Y; Lai J; Yu W; Zhang Y; Jin Z; Xu Y; Chen J; Zha X; Chen S; Yang L; Li Y
Sci China Life Sci; 2015 Dec; 58(12):1276-81. PubMed ID: 26423566
[TBL] [Abstract][Full Text] [Related]
10. The hematopoietic stem cell in chronic phase CML is characterized by a transcriptional profile resembling normal myeloid progenitor cells and reflecting loss of quiescence.
Bruns I; Czibere A; Fischer JC; Roels F; Cadeddu RP; Buest S; Bruennert D; Huenerlituerkoglu AN; Stoecklein NH; Singh R; Zerbini LF; Jäger M; Kobbe G; Gattermann N; Kronenwett R; Brors B; Haas R
Leukemia; 2009 May; 23(5):892-9. PubMed ID: 19158832
[TBL] [Abstract][Full Text] [Related]
11. BCR and BCR-ABL regulation during myeloid differentiation in healthy donors and in chronic phase/blast crisis CML patients.
Marega M; Piazza RG; Pirola A; Redaelli S; Mogavero A; Iacobucci I; Meneghetti I; Parma M; Pogliani EM; Gambacorti-Passerini C
Leukemia; 2010 Aug; 24(8):1445-9. PubMed ID: 20520635
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic inactivation of DLX4 is associated with disease progression in chronic myeloid leukemia.
Zhou JD; Wang YX; Zhang TJ; Yang DQ; Yao DM; Guo H; Yang L; Ma JC; Wen XM; Yang J; Lin J; Qian J
Biochem Biophys Res Commun; 2015 Aug; 463(4):1250-6. PubMed ID: 26086097
[TBL] [Abstract][Full Text] [Related]
13. Differences in BCL-X(L) expression and STAT5 phosphorylation in chronic myeloid leukaemia patients.
Gutiérrez-Castellanos S; Cruz M; Rabelo L; Godínez R; Reyes-Maldonado E; Riebeling-Navarro C
Eur J Haematol; 2004 Apr; 72(4):231-8. PubMed ID: 15089759
[TBL] [Abstract][Full Text] [Related]
14. [Methylation status of id4 gene promoter in patients with chronic myeloid leukemia].
Wang XR; Kang HY; Cen J; Li YH; Wang LL; Yu L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Dec; 18(6):1402-4. PubMed ID: 21176338
[TBL] [Abstract][Full Text] [Related]
15. [A clinical and laboratory study of chronic myeloid leukemia with atypical BCR-ABL fusion gene subtypes].
Gui X; Pan J; Qiu H; Cen J; Xue Y; Chen S; Shen H; Yao L; Zhang J; Wu Y; Chen Y
Zhonghua Xue Ye Xue Za Zhi; 2014 Mar; 35(3):210-4. PubMed ID: 24666486
[TBL] [Abstract][Full Text] [Related]
16. Molecular basis for therapeutic decisions in chronic myeloid leukemia patients after allogeneic bone marrow transplantation.
Román J; Alvarez MA; Torres A
Haematologica; 2000 Oct; 85(10):1072-82. PubMed ID: 11025600
[TBL] [Abstract][Full Text] [Related]
17. Expression pattern of key microRNAs in patients with newly diagnosed chronic myeloid leukemia in chronic phase.
Fallah P; Amirizadeh N; Poopak B; Toogeh G; Arefian E; Kohram F; Hosseini Rad SM; Kohram M; Teimori Naghadeh H; Soleimani M
Int J Lab Hematol; 2015 Aug; 37(4):560-8. PubMed ID: 25833191
[TBL] [Abstract][Full Text] [Related]
18. Myeloperoxidase cytochemical negativity: an unexpected but intrinsic property of blasts of all phases of chronic myeloid leukemia.
Anand M; Ghara N; Kumar R; Singh S; Sengar M; Panikar N; Raina V; Sharma A
Ann Hematol; 2005 Nov; 84(12):767-70. PubMed ID: 15990995
[TBL] [Abstract][Full Text] [Related]
19. Gene expression profiling of CD34+ cells identifies a molecular signature of chronic myeloid leukemia blast crisis.
Zheng C; Li L; Haak M; Brors B; Frank O; Giehl M; Fabarius A; Schatz M; Weisser A; Lorentz C; Gretz N; Hehlmann R; Hochhaus A; Seifarth W
Leukemia; 2006 Jun; 20(6):1028-34. PubMed ID: 16617318
[TBL] [Abstract][Full Text] [Related]
20. The proto-oncogene expression varies over the course of chronic myeloid leukemia.
Vidović A; Janković G; Colović M; Tomin D; Perunicić M; Bila J; Marković O; Bosković D
Hematology; 2008 Feb; 13(1):34-40. PubMed ID: 18534064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]